Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01829113 · ClinicalTrials.gov registry record · Phase 2
Phase II Trial of Carboplatin and Pemetrexed +/- OGX-427 in Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer
A Phase 2 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 155
- Enrollment target
NCT01829113 is a Phase 2 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 155 participants.
The verdict
NCT01829113, a Phase 2 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 155 participants
- Enrollment target
Study Summary
This randomized phase II study will compare the efficacy and safety of the combination of carboplatin and pemetrexed with and without OGX-427 in patients with previously untreated advanced non-squamous NSCLC.
Interventions
- DRUG Placebo
- DRUG OGX-427
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2013-07 |
| Est. Completion | 2017-04-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01829113
The ClinicalTrials.gov registry entry for NCT01829113 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 155 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01829113 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01829113 about?
NCT01829113 is a clinical study titled "Phase II Trial of Carboplatin and Pemetrexed +/- OGX-427 in Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer". This randomized phase II study will compare the efficacy and safety of the combination of carboplatin and pemetrexed with and without OGX-427 in patients with previously untreated advanced non-squamous NSCLC.
What is the current status of trial NCT01829113?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 155 participants. The study started on 2013-07. Estimated completion is 2017-04-19.
What interventions are being tested in trial NCT01829113?
The interventions under investigation include: Placebo (DRUG), OGX-427 (DRUG).
Who is sponsoring clinical trial NCT01829113?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.